FDA approves Proteus Digital Health's e-pills for dose monitoring

FDA approves Proteus Digital Health's e-pills for dose monitoring

An "ingestible sensor" doesn't sound like the tastiest of snacks, but soon it might be just what the doctor ordered. A tiny microchip which activates upon contact with stomach acid has recently been given the green light by health regulatory agencies in the US and Europe. When the sensor is swallowed, an external patch picks up its signal and shoots a message over to whoever it's supposed to. The technology is aimed at tackling an issue known in the healthcare biz as compliance -- or, following instructions. Correct timing and dose are important for many drugs, and lax schedules can be responsible for treatme nt failures or the development of nasty drug-resistant bugs. Although the necessary trials used placebo pills, one pharmaceutical heavyweight has already bagged a license to the technology for real-world applications. If the thought of passing microchips is troubling you more than the thought of eating them, no need to worry -- the kamikaze sensors dissolve in your stomach shortly after completing their mission.

Show full PR text

Proteus Digital Health Announces FDA Clearance of Ingestible Sensor

REDWOOD CITY, Calif. – July 30, 2012 – Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its ingestible sensor for marketing as a medical device. The ingestible sensor (formally referred to as the Ingestion Event Marker or IEM) is part of the Proteus digital health feedback system, an integrated, end-to-end personal health management system that is designed to help improve patients' he alth habits and connections to caregivers.

Proteus has worked collaboratively with the FDA since 2008 to determine the regulatory pathway for this innovation, which represents a new category of medical device and patient care. The application was ultimately processed in accordance with the de novo provisions of the Federal Food, Drug and Cosmetic Act for low-risk devices that have no predicate on the market.

"We are thrilled to have achieved this important milestone to market our ingestible sensor in the United States now, as well as in Europe," said Dr. George M. Savage, co-founder and chief medical officer at Proteus Digital Health. "We are very much looking forward to bringing the benefits of our ingestible sensor to the American public in the form of innovative product offerings."

"The FDA validation represents a major milestone in digital medicine. Directly digitizing pills, for the first time, in conjunction with our wireless infrastruc ture, may prove to be the new standard for influencing medication adherence and significantly aid chronic disease management," said Dr. Eric Topol, professor of genomics at The Scripps Research Institute and author of "The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Healthcare".

The Proteus ingestible sensor can be integrated into an inert pill or other ingested products, such as pharmaceuticals. Once the ingestible sensor reaches the stomach, it is powered by contact with stomach fluid and communicates a unique signal that determines identity and timing of ingestion. This information is transferred through the user's body tissue to a patch worn on the skin that detects the signal and marks the precise time an ingestible sensor has been taken. Additional physiologic and behavioral metrics collected by the patch include heart rate, body position and activity. The patch relays information to a mobile phone application. With the pa tient's consent, the information is accessible by caregivers and clinicians, helping individuals to develop and sustain healthy habits, families to make better health choices, and clinicians to provide more effective, data-driven care.

Engadget